Literature DB >> 25240415

Fluvastatin attenuated the effect of expression of β1 integrin in PAN-treated podocytes by inhibiting reactive oxygen species.

Jia Liu1, Bo Zhang, Yuping Chai, Yaguang Xu, Changying Xing, Xiaoyun Wang.   

Abstract

It is well accepted that β1 integrin plays a key role in maintaining normal podocytes form and functions; however, its mechanism of the potential protective effect remains unclear. Furthermore, the investigation and understanding of the non-lipid-dependent renal protection of Statins in addition to well-known lipid-lowering effect may provide the therapeutic utility and ultimately improve clinical outcome for patients with renal diseases. In the present study, we investigated the effect and mechanism of fluvastatin (FLV) on the expression of β1 integrin in puromycin aminonucleoside (PAN)-treated podocytes in vitro. Cultured human podocytes were treated with PAN, and/or different concentrations of FLV (1 × 10(-8)-1 × 10(-5 )mol/l), superoxide dismutase (SOD), or H2O2, respectively. The expression of β1 integrin and reactive oxygen species (ROS) in human podocytes under each experimental condition was evaluated by western blot, RT-PCR, and 2'7'-dichlorofluorescein 3'6'-diacetate, respectively. The viability of podocytes was also assessed by MTT colorimetry in the present study. The expression of β1 integrin was significantly decreased, and the synthesis of ROS was significantly increased in podocytes following either PAN or H2O2 treatment (p < 0.05). The up-regulation of β1 integrin and down-regulation of ROS were also observed in PAN-treated podocytes following lower concentrations of FLV or SOD treatment (p < 0.05, respectively). The cytotoxicity data derived from MTT assay revealed that lower podocyte viability was found in the presence of higher concentrations of FLV, PAN, or H2O2. Lower concentration of FLV or SOD can protect podocytes from being impaired by PAN treatment. FLV attenuated the podocyte injury induced by PAN and increased the production of β1 integrin in human podocytes in vitro. This underlying mechanism of FLV may be through inhibiting the activity of ROS in human podocytes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25240415     DOI: 10.1007/s11010-014-2220-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  44 in total

Review 1.  Rho GTPases and signaling networks.

Authors:  L Van Aelst; C D'Souza-Schorey
Journal:  Genes Dev       Date:  1997-09-15       Impact factor: 11.361

2.  Roles of active oxygen species in glomerular epithelial cell injury in vitro caused by puromycin aminonucleoside.

Authors:  M Kawaguchi; M Yamada; H Wada; T Okigaki
Journal:  Toxicology       Date:  1992       Impact factor: 4.221

3.  Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats.

Authors:  S D Ricardo; J F Bertram; G B Ryan
Journal:  J Am Soc Nephrol       Date:  1994-06       Impact factor: 10.121

4.  Simvastatin combined with nifedipine enhances endothelial cell protection by inhibiting ROS generation and activating Akt phosphorylation.

Authors:  Xiao-niao Chen; Jun Xu; Zhe Feng; Ming Fan; Jing-yao Han; Zhuo Yang
Journal:  Acta Pharmacol Sin       Date:  2010-06-21       Impact factor: 6.150

Review 5.  Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)

Authors:  D Kerjaschki; T J Neale
Journal:  J Am Soc Nephrol       Date:  1996-12       Impact factor: 10.121

6.  Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells.

Authors:  Wenjian Wang; Yin Wang; Jianyin Long; Jinrong Wang; Sandra B Haudek; Paul Overbeek; Benny H J Chang; Paul T Schumacker; Farhad R Danesh
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

Review 7.  Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities.

Authors:  Shane R Thomas; Paul K Witting; Grant R Drummond
Journal:  Antioxid Redox Signal       Date:  2008-10       Impact factor: 8.401

8.  Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation.

Authors:  Cecile Dessapt; Marc Olivier Baradez; Anthea Hayward; Alessandra Dei Cas; Stephen M Thomas; Giancarlo Viberti; Luigi Gnudi
Journal:  Nephrol Dial Transplant       Date:  2009-05-06       Impact factor: 5.992

9.  Podocyte flattening and disorder of glomerular basement membrane are associated with splitting of dystroglycan-matrix interaction.

Authors:  Kenichiro Kojima; Agnes Davidovits; Helga Poczewski; Brigitte Langer; Shunya Uchida; Katalyn Nagy-Bojarski; Anny Hovorka; Roland Sedivy; Dontscho Kerjaschki
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

10.  Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity.

Authors:  Ambra Pozzi; George Jarad; Gilbert W Moeckel; Sergio Coffa; Xi Zhang; Leslie Gewin; Vera Eremina; Billy G Hudson; Dorin-Bogdan Borza; Raymond C Harris; Lawrence B Holzman; Carrie L Phillips; Reinhard Fassler; Susan E Quaggin; Jeffrey H Miner; Roy Zent
Journal:  Dev Biol       Date:  2008-01-31       Impact factor: 3.582

View more
  3 in total

Review 1.  Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Pediatr Nephrol       Date:  2015-05-05       Impact factor: 3.714

2.  Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.

Authors:  Adrian Vlad; Mihaela Vlad; Ligia Petrica; Sorin Ursoniu; Florica Gadalean; Roxana Popescu; Daliborca Vlad; Victor Dumitrascu; Gheorghe Gluhovschi; Cristina Gluhovschi; Silvia Velciov; Flaviu Bob; Petru Matusz; Alina Secara; Anca Simulescu; Dragos Catalin Jianu
Journal:  Ren Fail       Date:  2016-11-13       Impact factor: 2.606

3.  Plectin protects podocytes from adriamycin-induced apoptosis and F-actin cytoskeletal disruption through the integrin α6β4/FAK/p38 MAPK pathway.

Authors:  Yongliang Ni; Xin Wang; Xiaoxuan Yin; Yan Li; Xigao Liu; Haixin Wang; Xiangjv Liu; Jun Zhang; Haiqing Gao; Benkang Shi; Shaohua Zhao
Journal:  J Cell Mol Med       Date:  2018-09-06       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.